AMA Encourages Oral Contraceptive OTC Options In Policy Update
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
AMA members agree to strengthen association's policy language supporting approval and reimbursement of OTC contraceptives.
You may also be interested in...
AMA Shares OTC Birth Control Diagnosis With FDA
American College of Obstetricians and Gynecologists proposed amending existing AMA policy in anticipation of Perrigo’s HRA business submitting NDA to FDA for OTC switch of progestin-only daily oral contraceptive the end of 2022.
Teva Plan B OTC Application Fails Political Test After Clearing FDA Hurdle
HHS Secretary Sebelius says Teva must show more evidence of how young adolescent females would use Plan B One-Step as an OTC. But obtaining such clinical data for the emergency contraceptive – in excess of what FDA already needed to approve it – appears nearly impossible, experts say.